Final results from the large sunitinib global expanded-access trial
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.06/19/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 19, 2015 Category: Cancer & Oncology Source Type: news

Pathways in Renal Cell Carcinoma: An Animated View
Learn more about a type of kidney cancer called advanced renal cell carcinoma (aRCC) and the pathways involved in the disease in this animated whiteboard...06/18/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 18, 2015 Category: Cancer & Oncology Source Type: news

Future perspectives for mTOR inhibitors in renal cell cancer
Everolimus is a mTOR inhibitor that demonstrates antitumor and antiangiogenic activities.06/16/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 16, 2015 Category: Cancer & Oncology Source Type: news

Argos Therapeutics: A Cure For Cancer?
AGS-003 for metastatic renal cell carcinoma ((mRCC)) in Phase III with the full patient enrollment expected in Q2-2014. The final results should come out in the second half of 2016. The primary endpoint of the study is the overall survival.05/23/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 23, 2015 Category: Cancer & Oncology Source Type: news

FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma
Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population.05/21/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 21, 2015 Category: Cancer & Oncology Source Type: news

2015 ASCO Annual Meeting
Abstracts in genitourinary cancers, including: Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US...05/14/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 14, 2015 Category: Cancer & Oncology Source Type: news

Revealing kidney cancer's secret
(University of California - Davis Health System) An international team of scientists, led by UC Davis nephrologist Robert Weiss, have used a sophisticated combination of proteomics and metabolomics to show how renal cell carcinoma reprograms its metabolism and evades the immune system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2015 Category: Cancer & Oncology Source Type: news

2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
Dateline City: KENILWORTH, N.J. New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), kno...
Source: Merck.com - Corporate News - May 13, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news

2015 Conquer Cancer Foundation of ASCO Young Investigator Award Funded by Kidney Cancer Association
Matthew Campbell, MD Chief Fellow, Hematology/Oncology Fellowship, UT MD Anderson Cancer Center New agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the ...
Source: Kidney Cancer Association - May 11, 2015 Category: Cancer & Oncology Source Type: news

2015 Conquer Cancer Foundation of ASCO Young Investigator Award Funded by Kidney Cancer Association
Matthew Campbell, MD Chief Fellow, Hematology/Oncology Fellowship, UT MD Anderson Cancer CenterNew agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the an...
Source: Kidney Cancer Association - May 11, 2015 Category: Urology & Nephrology Source Type: news

Analysis of Gene Expression of RCC by DNA Microaray in Patients treated with Sunitinib
Gene Evaluation of DNA expression from snap-frozen renal cell cancer tissue from 5 patients with locally advanced non-metastatic tumors, submitted to nephrectomy after being treated with 2 cycles of neoadjuvant Sunitinib...05/11/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 11, 2015 Category: Cancer & Oncology Source Type: news

2015 Conquer Cancer Foundation of ASCO Young Investigator Award
Layperson Summary  New agents called immune check point inhibitors have been FDA approved in the treatment of metastatic melanoma and metastatic squamous cell lung cancer. These agents have shown exciting activity in bladder, kidney, and a variety of other cancers in early clinical studies and are being explored in larger studies. The first of these agents, ipilimumab, is an antibody that binds to CTLA-4, a molecule that is increased by T cells responding to a stimulus, to help shut off the immune response. When the anti-body binds to CTLA-4, the immune system is able to stay activated an...
Source: Kidney Cancer Association - May 10, 2015 Category: Cancer & Oncology Source Type: news

Dr. Thomas Hutson on Drug Sequencing in Renal Cell Carcinoma
Seven new agents have been approved for renal cell over a relatively short period of time. That has made it difficult to determine which drugs should be used for first, says Hutson.04/28/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 28, 2015 Category: Cancer & Oncology Source Type: news

Metastatic renal cell carcinoma mimicking diverticulitis
We present an unusual case of metastatic renal cell carcinoma (RCC) mimicking diverticulitis in a 76-year-old man with a 16-year history of chronic lymphocytic leukaemia (CLL) and a 2 cm left renal mass.04/28/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 28, 2015 Category: Cancer & Oncology Source Type: news

Promising Data on First Inhibitor of HIF-2a for Renal Cell Carcinoma
Preclinical data indicates that lead investigational compound PT2385 suppresses gene expression essential for tumor growth, proliferation, and angiogenesisPhase 1 study of PT2385 ongoing; first clinical stage HIF-2a program.04/20/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 20, 2015 Category: Cancer & Oncology Source Type: news

Exelixis Entering Critical Six-Month Period
Cabozantinib is also in 45 ongoing or planned clinical trials, including pivotal Phase 3 trials in metastatic renal cell cancer (mRCC) in METEOR and advanced hepatocellular cancer (CELESTIAL).04/02/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 3, 2015 Category: Cancer & Oncology Source Type: news

New Mesothelioma Treatment Options Are Emerging for Patients
Although no definitive cure is in sight, the treatment of malignant pleural mesothelioma has entered a promising, much-anticipated phase that goes beyond the multimodal approach that has been the standard of care at specialty centers for the past several years. There is new hope on the horizon. Thoracic surgeon and renowned mesothelioma specialist Dr. Robert Cameron, along with scientist Raymond Wong, Ph.D., and thoracic and cardia surgeon Dr. Svetlana Kotova, recently detailed the changing face of therapy in a paper they co-authored and published in the Cancer Management Research Journal . "With all the ongoing r...
Source: Asbestos and Mesothelioma News - April 2, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Alternating sunitinib, everolimus not supported in advanced RCC
Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma (RCC), failed to meet the prespecified criteria for use or continued development.03/26/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 26, 2015 Category: Cancer & Oncology Source Type: news

Lpath's kidney cancer drug fails mid-stage trial
(Reuters) - Drug developer Lpath Inc said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed to meet its main goal in a mid-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - March 24, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Urine Proteins May Help Spot Renal CancerUrine Proteins May Help Spot Renal Cancer
Urine concentrations of two tumor-specific proteins may have "substantial potential" for detecting renal cell carcinoma (RCC) in some patients, a new study suggests. Reuters Health Information (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - March 24, 2015 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

Scientists pioneer new drug regimen that reduces toxicities for renal cancer patients
Conclusive results have been revealed in reducing toxicities for Asian patients with metastatic renal cell carcinoma or cancer that has spread beyond the kidney. The findings have revolutionized the standard protocol for patient management in NCCS with an attenuated-dose regimen of sunitinib for patients with mRCC. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 18, 2015 Category: Science Source Type: news

NCCS pioneers new drug regimen which reduces toxicities for renal cancer patients
(SingHealth) A study led by the Genitourinary oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma or cancer that has spread beyond the kidney. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2015 Category: Cancer & Oncology Source Type: news

Obesity Triggers Enhanced MDSC Accumulation in Murine Renal Tumors
Obesity is one of the leading risk factors for developing renal cell carcinoma, an immunogenic tumor that is treated clinically with immunostimulatory therapies. Currently, however, the mechanisms linking obesity with renal cancer incidence are unclear.03/17/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 17, 2015 Category: Cancer & Oncology Source Type: news

Trends in Renal Cell Carcinoma Incidence and Mortality
Renal cell carcinoma (RCC) incidence rates are higher in developed countries, where up to half of the cases are discovered incidentally. Declining mortality trends have been reported in highly developed countries since the 1990s.03/16/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 16, 2015 Category: Cancer & Oncology Source Type: news

High BMI Boosts Survival in Metastatic Renal CancerHigh BMI Boosts Survival in Metastatic Renal Cancer
Excess weight is associated with a higher risk for renal cell carcinoma, but it may also help patients survive longer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A new study for people with Renal Cell Carcinoma (RCC)
This study will explore the effectiveness of the experimental drug known as CRLX101 combined with bevacizumab (Avastin), in patients with metastatic renal cell carcinoma (RCC).03/04/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2015 Category: Cancer & Oncology Source Type: news

Lycopene may ward off kidney cancer in older women
A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma...03/03/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 3, 2015 Category: Cancer & Oncology Source Type: news

Novel Combination 'Encouraging' in Advanced Kidney CancerNovel Combination 'Encouraging' in Advanced Kidney Cancer
An investigational antiangiogenic inhibitor of the ALK1 pathway and a VEGF inhibitor showed promising activity and a good safety profile in advanced renal cell carcinoma. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lycopene may ward off kidney cancer in older women
A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer, scientists report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 2, 2015 Category: Science Source Type: news

Lycopene may ward off kidney cancer in older women
(Wayne State University - Office of the Vice President for Research) A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 2, 2015 Category: Cancer & Oncology Source Type: news

Body Mass Index Predicts Survival
Body mass index (BMI) predicts survival and overall response (ORR) rates in patients with metastatic clear cell renal cell carcinoma, according to authors of an external validation data analysis (Abstract 405) presented during the 2015 Genitourinary Cancers Symposium.03/01/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 1, 2015 Category: Cancer & Oncology Source Type: news

Phase Ib DART Trial Examines Combination Axitinib and Dalantercept
Interfering with two different stages of angiogenesis concurrently proves promising in clear cell renal cell carcinoma (RCC) based on early clinical results from the DART trial. In this phase Ib study of combined treatment with axitinib and dalantercept, objective responses have been observed in 25% of patients, along with a preliminary median progression-free survival duration of 8.3 months (Abstract 407).03/01/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 1, 2015 Category: Cancer & Oncology Source Type: news

Combination Therapy with Sunitinib and Gemcitabine in Rapidly Progressive mRCC
Standard single-agent treatment options offer meager prospects for metastatic sarcomatoid renal cell carcinoma (RCC) and poor-risk RCC, both of which demonstrate aggressive tumor biology and rapid clinical disease progression. However, results of a single-arm, open-label, phase II trial suggest that combining select treatment options may deliver the necessary punch to keep these aggressive forms of RCC in check (Abstract 408).03/01/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 1, 2015 Category: Cancer & Oncology Source Type: news

ASCO GU Keynote: Future Clinical Trials in Renal Cell Cancer
Daniel J. George, MD, of Duke Cancer Institute, gives an overview of what is on the horizon in renal cell cancer (RCC) research. Topics discussed include emerging clinical trials, how to move forward with predictive biomarkers, clinical outcomes for RCC trials, and unmet needs in advanced RCC that Dr. George describes as being “imminently attainable.”03/01/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 1, 2015 Category: Cancer & Oncology Source Type: news

Andrew Futreal receives Jack and Beverly Randall Prize
The University of Texas MD Anderson Cancer Center has awarded Andrew Futreal, Ph.D., professor of Genomic Medicine, the inaugural Jack and Beverly Randall Prize for Excellence in Cancer Research. Futreal is recognized internationally as a pioneer in large-scale systematic cancer genomics, which led to the identification of the BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes, BRAF mutations in melanoma, ERBB2 mutations in non-small cell lung cancer and multiple new cancer genes in renal cell carcinoma.  (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - February 26, 2015 Category: Cancer & Oncology Source Type: news

VEGF Inhibitors Disappoint in Adjuvant Renal Cell CarcinomaVEGF Inhibitors Disappoint in Adjuvant Renal Cell Carcinoma
Sorafenib and sunitinib do not prolong disease-free survival in patients with completely resected, locally advanced kidney cancer at high risk for recurrence. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 24, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Sunitinib, sorafenib of no benefit in ECOG-ACRIN renal cell trial
Philadelphia, Pa., February 23, 2015, 5:00 PM – Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent® (sunitinib) or Nexavar® (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence... https://secure.kidneycancer.org/neon/resource/kca/files/ECOG-ACRIN_PressRelease_E2805_renal-cell-trial.pdf02/24/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 24, 2015 Category: Cancer & Oncology Source Type: news

Sunitinib, sorafenib of no benefit in ECOG-ACRIN renal cell trial
Philadelphia, Pa., February 23, 2015, 5:00 PM– Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent® (sunitinib) or Nexavar® (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence...https://secure.kidneycancer.org/neon/resource/kca/files/ECOG-ACRIN_PressRelease_E2805_renal-cell-trial.pdf02/24/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 24, 2015 Category: Urology & Nephrology Source Type: news

Posttraumatic stress and depressive symptoms in renal cell carcinoma
he purpose of this study was to examine the prevalence of posttraumatic stress symptoms (PTSS) in patients with renal cell carcinoma (RCC), the associations and co–occurrence between PTSS, depressive, and other cancer–related symptoms...02/23/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 23, 2015 Category: Cancer & Oncology Source Type: news

Sunitinib, sorafenib of no benefit in ECOG-ACRIN renal cell trial
(ECOG-ACRIN Cancer Research Group) Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced. Both of these oral drugs are widely used in helping patients with metastatic renal cell carcinoma, commonly called kidney cancer, live longer with their disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2015 Category: Global & Universal Source Type: news

Phase 2 clinical trial on volitinib in papillary renal cell carcinoma
At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC).02/21/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 21, 2015 Category: Cancer & Oncology Source Type: news

Biomarker for patients with renal cell carcinoma
Microarray experiments were performed to determine the expression of 32,183 lncRNA transcripts belonging to 17,512 lncRNAs in 15 corresponding normal and malignant renal tissues.02/19/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2015 Category: Cancer & Oncology Source Type: news

Lycopene inversely linked to renal cell carcinoma
For postmenopausal women, lycopene intake seems to be inversely associated with the risk of renal cell carcinoma (RCC), according to a study published in the Feb. 15 issue of Cancer.02/17/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 17, 2015 Category: Cancer & Oncology Source Type: news

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool
Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We sought to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therapy after progression on first-line targeted therapy.02/12/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 12, 2015 Category: Cancer & Oncology Source Type: news

Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma
Objective: To evaluate the clinical efficacy of sorafenib as preoperative neoadjuvant therapy in patients with high risk renal cell carcinoma (RCC).02/05/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 5, 2015 Category: Cancer & Oncology Source Type: news

Renal Cancer Drug Lenvatinib Meets Primary Endpoint
The phase II part of a phase I/II clinical trial (Study 205) of the anticancer agent lenvatinib mesylate (Eisai Co., Ltd.) in unresectable advanced or metastatic renal cell carcinoma (RCC) has met its primary endpoint.01/31/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 31, 2015 Category: Cancer & Oncology Source Type: news